Peripheral Biomarkers of Excitotoxicity in Neurological Diseases

  • Lucio Tremolizzo
  • Gessica Sala
  • Carlo Ferrarese

Since the proposal that excessive glutamater-gic stimulation, also known as excitotoxicity, could be responsible for neuronal suffering and death, several studies have repeatedly confirmed the key role of this mechanism in the pathogenesis of different neurological diseases. Therefore, it is conceivable that assessing the glutamatergic function directly in patients could be extremely useful for early diagnosis, prognostic evaluation, and optimization of therapeutics interventions. For example, a possibility is offered by measuring glutamate levels directly in plasma, in patients affected by stroke, amyotrophic lateral sclerosis, Alzheimer's disease, and AIDS dementia complex, among other diseases. However, the possibility of directly assessing functional glutamatergic parameters, such as the amino acid reuptake in ex vivo cells following different stimuli, would probably mirror closely the actual damage operative in single patients. In this chapter our findings regarding excitotoxicity biomarkers in peripheral ex vivo cells, such as platelets and fibroblasts, will be described focusing on different neurological diseases, together with a review of the available literature.


Excitotoxicity peripheral models glutamate neurological diseases biomarkers 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Curtis DR, Phillis JW, Watkins JC. Chemical excitation of spinal neurones. Nature. 1959;183:611–612PubMedGoogle Scholar
  2. 2.
    Curtis DR, Watkins JC. The excitation and depression of spinal neurones by structurally related amino acids. J Neurochem. 1960;6:117–141PubMedGoogle Scholar
  3. 3.
    Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol. 1957;58:193–201PubMedGoogle Scholar
  4. 4.
    Mody I, MacDonald JF. NMDA receptor-dependent excito-toxicity: the role of intracellular Ca2+ release. Trends Pharmacol Sci. 1995;16:356–359PubMedGoogle Scholar
  5. 5.
    Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol. 1992;31:119–130PubMedGoogle Scholar
  6. 6.
    Beal MF. Mechanisms of excitotoxicity in neurologic diseases. FASEB J. 1992;6:3338–3344PubMedGoogle Scholar
  7. 7.
    Ferrarese C, Beal MF, eds. Excitotoxicity in neurological diseases: new therapeutic challenge, Kluwer, Boston, 2003Google Scholar
  8. 8.
    Olney JW. Brain lesions, obesity and other disturbances in mice treated with monosodium glutamate. Science. 1969;164:719–721PubMedGoogle Scholar
  9. 9.
    Olney JW. Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry. 1989;26:505–525PubMedGoogle Scholar
  10. 10.
    Cotman CW, Monaghan DT, Ganong AH. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annu Rev Neurosci. 1988;11:61–80PubMedGoogle Scholar
  11. 11.
    Skerry TM, Genever PG. Glutamate signalling in non-neu-ronal tissues. Trends Pharmacol Sci. 2001;22:174–181PubMedGoogle Scholar
  12. 12.
    Hisano S. Vesicular glutamate transporters in the brain. Anat Sci Int. 2003;78:191–204PubMedGoogle Scholar
  13. 13.
    Torgner I, Kvamme E. Synthesis of transmitter glutamate and the glial-neuron interrelationship. Mol Chem Neuropathol. 1990;12:11–17PubMedGoogle Scholar
  14. 14.
    Broer S, Brookes N. Transfer of glutamine between astro-cytes and neurons. J Neurochem. 2001;77:705–719PubMedGoogle Scholar
  15. 15.
    Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26:438–458PubMedGoogle Scholar
  16. 16.
    Daw NW, Stein PS, Fox K. The role of NMDA receptors in information processing. Annu Rev Neurosci. 1993;16:207–222PubMedGoogle Scholar
  17. 17.
    Massieu L, Garcia O. The role of excitotoxicity and metabolic failure in the pathogenesis of neurological disorders. Neurobiology. 1998;6:99–108PubMedGoogle Scholar
  18. 18.
    Williams K. Interactions of polyamines with ion channels. Biochem J. 1997;325:289–297PubMedGoogle Scholar
  19. 19.
    Li YV, Hough CJ, Sarvey JM. Do we need zinc to think? Sci STKE. 2003;182:19Google Scholar
  20. 20.
    Lipton SA, Singel DJ, Stamler JS. Nitric oxide in the central nervous system. Prog Brain Res. 1994;103:359–364PubMedGoogle Scholar
  21. 21.
    Mattson MP. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurode-generative disorders. Neuromolecular Med. 2003;3:65–94PubMedGoogle Scholar
  22. 22.
    Lazarewicz JW, Wroblewski JT, Palmer ME, et al. Activation of N-methyl-D-aspartate-sensitive glutamate receptors stimulates arachidonic acid release in primary cultures of cerebellar granule cells. Neuropharmacology. 1988;27:765–769PubMedGoogle Scholar
  23. 23.
    Garthwaite J, Garthwaite G, Palmer RM, et al. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol. 1989;172:413–416PubMedGoogle Scholar
  24. 24.
    Melcher T, Geiger JR, Jonas P, et al. Analysis of molecular determinants in native AMPA receptors. Neurochem Int. 1996;28:141–144PubMedGoogle Scholar
  25. 25.
    Bredt DS, Nicoll RA. AMPA receptor trafficking at excitatory synapses. Neuron. 2003;40:361–379PubMedGoogle Scholar
  26. 26.
    Huettner JE. Kainate receptors and synaptic transmission. Prog Neurobiol. 2003;70:387–407PubMedGoogle Scholar
  27. 27.
    Mori H, Mishina M. Roles of diverse glutamate receptors in brain functions elucidated by subunit-specific and region-specific gene targeting. Life Sci. 2003;74:329–336PubMedGoogle Scholar
  28. 28.
    Hinoi E, Takarada T, Ueshima T, et al. Glutamate signaling in peripheral tissues. Eur J Biochem. 2004;271:1–13PubMedGoogle Scholar
  29. 29.
    Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65: 1–105PubMedGoogle Scholar
  30. 30.
    Beretta S, Begni B, Ferrarese C. Pharmacological manipulation of glutamate transport. Drug News Perspect. 2003; 16:435–445PubMedGoogle Scholar
  31. 31.
    O'Shea RD. Roles and regulation of glutamate transporters in the central nervous system. Clin Exp Pharmacol Physiol. 2002;29:1018–1023PubMedGoogle Scholar
  32. 32.
    Amara SG, Fontana AC. Excitatory amino acid transporters: keeping up with glutamate. Neurochem Int. 2002;41:313–318PubMedGoogle Scholar
  33. 33.
    Sato H, Tamba M, Ishii T, et al. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem. 1999;274:11455–11458PubMedGoogle Scholar
  34. 34.
    Flynn J, McBean GJ. Kinetic and pharmacological analysis of L-[35 S] cystine transport into rat brain synaptosomes. Neurochem Int. 2000;36:513–521PubMedGoogle Scholar
  35. 35.
    Baker DA, Shen H, Kalivas PW. Cystine/glutamate exchange serves as the source for extracellular glutamate: modifications by repeated cocaine administration. Amino Acids. 2002;23:161–162PubMedGoogle Scholar
  36. 36.
    Bannai S. Exchange of cystine and glutamate across plasma membrane of human fibroblasts. J Biol Chem. 1986;261: 2256–2263PubMedGoogle Scholar
  37. 37.
    Danbolt NC, Holmseth S, Skar A, et al. Glutamate uptake transporters. In: Ferrarese C, Beal MF, eds. Excitotoxicity in neurological diseases: new therapeutic challenge, Kluwer, Boston 2003Google Scholar
  38. 38.
    Fiermonte G, Palmieri L, Todisco S, et al. Identification of the mitochondrial glutamate transporter. Bacterial expression, reconstitution, functional characterization, and tissue distribution of two human isoforms. J Biol Chem. 2002;277: 19289–19294PubMedGoogle Scholar
  39. 39.
    Munir M, Correale DM, Robinson MB. Substrate-induced up-regulation of Na(+)-dependent glutamate transport activity. Neurochem Int. 2000;37:147–162PubMedGoogle Scholar
  40. 40.
    Duan S, Anderson CM, Stein BA, et al. Glutamate induces rapid upregulation of astrocyte glutamate transport and cell-surface expression of GLAST. J Neurosci. 1999; 19:10193–10200PubMedGoogle Scholar
  41. 41.
    Fine SM, Angel RA, Perry SW, et al. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astro-cytes. Implications for pathogenesis of HIV-1 dementia. J Biol Chem. 1996;271:15303–15306PubMedGoogle Scholar
  42. 42.
    Keller JN, Mark RJ, Bruce AJ, et al. 4-hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synapto-somes. Neuroscience. 1997;80:685–696PubMedGoogle Scholar
  43. 43.
    Springer JE, Azbill RD, Mark RJ, et al. 4-hydroxynonenal, a lipid peroxidation product, rapidly accumulates following traumatic spinal cord injury and inhibits glutamate uptake. J Neurochem. 1997;68:2469–2476PubMedGoogle Scholar
  44. 44.
    Chen W, Aoki C, Mahadomrongkul V, et al. Expression of a variant form of the glutamate transporter GLT1 in neuronal cultures and in neurons and astrocytes in the rat brain. J Neurosci. 2002;22:2142–2152PubMedGoogle Scholar
  45. 45.
    Schmitt A, Asan E, Lesch KP, et al. A splice variant of glutamate transporter GLT1/EAAT2 expressed in neurons: cloning and localization in rat nervous system. Neuroscience. 2002;109:45–61PubMedGoogle Scholar
  46. 46.
    Northington FJ, Traystman RJ, Koehler RC, et al. GLT1, glial glutamate transporter, is transiently expressed in neurons and develops astrocyte specificity only after midges-tation in the ovine fetal brain. J Neurobiol. 1999; 39:515–526PubMedGoogle Scholar
  47. 47.
    Rauen T, Fischer F, Wiessner M. Glia-neuron interaction by high-affinity glutamate transporters in neurotransmission. Adv Exp Med Biol. 1999;468:81–95PubMedGoogle Scholar
  48. 48.
    Lehre KP, Danbolt NC. The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain. J Neurosci. 1998;18:8751–8757PubMedGoogle Scholar
  49. 49.
    Conti F, DeBiasi S, Minelli A, et al. EAAC1, a high-affinity glutamate transporter, is localized to astrocytes and gabaer-gic neurons besides pyramidal cells in the rat cerebral cortex. Cereb Cortex. 1998;8:108–116PubMedGoogle Scholar
  50. 50.
    Peghini P, Janzen J, Stoffel W. Glutamate transporter EAAC-1-deficient mice develop dicarboxylic aminoaciduria and behavioral abnormalities but no neurodegeneration. EMBO J. 1997;16:3822–3832PubMedGoogle Scholar
  51. 51.
    Tanaka K, Watase K, Manabe T, et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science. 1997;276:1699–1702PubMedGoogle Scholar
  52. 52.
    Dehnes Y, Chaudhry FA, Ullensvang K, et al. The glutamate transporter EAAT4 in rat cerebellar Purkinje cells: a gluta-mate-gated chloride channel concentrated near the synapse in parts of the dendritic membrane facing astroglia. J Neurosci. 1998;18:3606–3619PubMedGoogle Scholar
  53. 53.
    Marie H, Billups D, Bedford FK, et al. The amino terminus of the glial glutamate transporter GLT-1 interacts with the LIM protein Ajuba. Mol Cell Neurosci. 2002;19:152–164PubMedGoogle Scholar
  54. 54.
    Lin CI, Orlov I, Ruggiero AM, et al. Modulation of the neuronal glutamate transporter EAAC1 by the interacting protein GTRAP3–18. Nature. 2001;410:84–88PubMedGoogle Scholar
  55. 55.
    Jackson M, Song W, Liu M Y, et al. Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteins. Nature. 2001;410:89–93PubMedGoogle Scholar
  56. 56.
    Massieu L, Morales-Villagran A, Tapia R. Accumulation of extracellular glutamate by inhibition of its uptake is not sufficient for inducing neuronal damage: an in vivo microdialy-sis study. J. Neurochem. 1995;64:2262–2272PubMedGoogle Scholar
  57. 57.
    DiFrancesco JC, Cooper JM, Lam A, et al. MELAS mito-chondrial DNA mutation A3243G reduces glutamate transport in cybrids cell lines. Exp Neurol. 2008;212:152–156PubMedGoogle Scholar
  58. 58.
    Tremolizzo L, Beretta S, Ferrarese C. Peripheral markers of glutamatergic dysfunction in neurological diseases: focus on ex vivo tools. Crit Rev Neurobiol. 2004;16:141–146PubMedGoogle Scholar
  59. 59.
    Shulman RG. Functional imaging studies: linking mind and basic neuroscience. Am J Psychiatry. 2001;158:11–20PubMedGoogle Scholar
  60. 60.
    Petroff OA, Errante LD, Rothman DL, et al. Glutamate-glutamine cycling in the epileptic human hippocampus. Epilepsia. 2002;43:703–710PubMedGoogle Scholar
  61. 61.
    Pioro EP, Majors AW, Mitsumoto H, et al. 1H-MRS evidence of neurodegeneration and excess glutamate + glu-tamine in ALS medulla. Neurology. 1999;53:71–79PubMedGoogle Scholar
  62. 62.
    Taylor-Robinson SD, Turjanski N, Bhattacharya S, et al. A proton magnetic resonance spectroscopy study of the stria-tum and cerebral cortex in Parkinson's disease. Metab Brain Dis. 1999;14:45–55PubMedGoogle Scholar
  63. 63.
    Berger C, Annecke A, Aschoff A, et al. Neurochemical monitoring of fatal middle cerebral artery infarction. Stroke. 1999;30:460–463PubMedGoogle Scholar
  64. 64.
    Berger C, Schabitz WR, Georgiadis D, et al. Effects of hypothermia on excitatory amino acids and metabolism in stroke patients: a microdialysis study. Stroke. 2002;33:519–524PubMedGoogle Scholar
  65. 65.
    Schulz MK, Wang LP, Tange M, et al. Cerebral microdialy-sis monitoring: determination of normal and ischemic cerebral metabolisms in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 2000;93:808–814PubMedGoogle Scholar
  66. 66.
    Hutchinson PJ, O'Connell MT, Al-Rawi PG, et al. Increases in GABA concentrations during cerebral ischaemia: a microdialysis study of extracellular amino acids. J Neurol Neurosurg Psychiatry. 2002;72:99–105PubMedGoogle Scholar
  67. 67.
    Vespa P, Prins M, Ronne-Engstrom E, et al. Increase in extracellular glutamate caused by reduced cerebral perfusion pressure and seizures after human traumatic brain injury: a microdialysis study. J Neurosurg. 1998;89:971–982PubMedGoogle Scholar
  68. 68.
    Stahl N, Mellergard P, Hallstrom A, et al. Intracerebral microdialysis and bedside biochemical analysis in patients with fatal traumatic brain lesions. Acta Anaesthesiol Scand. 2001;45:977–985PubMedGoogle Scholar
  69. 69.
    Ferrarese C, Pecora N, Frigo M, et al. Assessment of reliability and biological significance of glutamate levels in cerebrospinal fluid. Ann Neurol. 1993;33:316–319PubMedGoogle Scholar
  70. 70.
    Espey MG, Basile AS, Heaton RK, et al. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology. 2002;58:1439PubMedGoogle Scholar
  71. 71.
    Da Prada M, Cesura AM, Launay JM, et al. Platelets as a model for neurones? Experientia. 1988;44:115–126PubMedGoogle Scholar
  72. 72.
    Di Luca M, Colciaghi F, Pastorino L, et al. Platelets as a peripheral district where to study pathogenetic mechanism of Alzheimer disease: the case of amyloid precursor protein. Eur J Pharmacol. 2000;405:277–283PubMedGoogle Scholar
  73. 73.
    Parnetti L, Reboldi GP, Santucci C, et al. Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders. Aging. 1994;6:201–207PubMedGoogle Scholar
  74. 74.
    Bongioanni P, Donato M, Castagna M, et al. Platelet phenol-sulphotransferase activity, monoamine oxidase activity and peripheral-type benzodiazepine binding in demented patients. J Neural Transm. 1996;103:491–501PubMedGoogle Scholar
  75. 75.
    Inestrosa NC, Alarcón R, Arriagada J, et al. Platelet of Alzheimer patients: increased counts and subnormal uptake and accumulation of [14C]5-hydroxytryptamine. Neurosci Lett. 1993;163:8–10PubMedGoogle Scholar
  76. 76.
    Zubenko GS, Teply I, Winwood E, et al. Prospective study of increased platelet membrane fluidity as a risk factor for Alzheimer's disease: results at 5 years. Am J Psychiatry. 1996;153:420–423PubMedGoogle Scholar
  77. 77.
    Rosenberg RN, Baskin F, Fosmire JA, et al. Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol. 1997;54:139–144PubMedGoogle Scholar
  78. 78.
    Di Luca M, Pastorino L, Bianchetti A, et al. Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol. 1998;55:1195–1200PubMedGoogle Scholar
  79. 79.
    Bongioanni P, Castagna M, Mondino C, et al. Platelet and lymphocyte benzodiazepine binding in patients with Alzheimer's disease. Exp Neurol. 1997;146:560–566PubMedGoogle Scholar
  80. 80.
    D'Andrea G, Canazi AR, Ferro-Milone F, et al. Platelet levels of glutamate and aspartate in normal subjects. Stroke. 1989;20:299–300PubMedGoogle Scholar
  81. 81.
    Yang M, Srikiatkhachorn A, Anthony M, et al. Serotonin stimulates megakaryocytopoiesis via the 5-HT2 receptor. Blood Coagul Fibrinolysis. 1996;7:127–133PubMedGoogle Scholar
  82. 82.
    Mangano RM, Schwarcz R. The human platelet as a model for the glutamatergic neuron: platelet uptake of L-Glutamate. J Neurochem. 1981;36:1067–1076PubMedGoogle Scholar
  83. 83.
    Sherif FM. GABA-transaminase in brain and blood platelets: basic and clinical aspects. Prog Neuropsycopharmacol Biol Psychiatry. 1994;18:1219–1233Google Scholar
  84. 84.
    Altamura CA, Mauri MC, Ferrara A, et al. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry. 1993;150:1731–1733PubMedGoogle Scholar
  85. 85.
    Franconi F, Miceli M, De Montis MG, et al. NMDA receptors play an antiaggregating role in human platelets. Thromb Haemost. 2000;76:84–87Google Scholar
  86. 86.
    Morrell CN, Sun H, Ikeda M, et al. Glutamate mediates platelet activation through the AMPA receptor. J Exp Med. 2008;205:575–584PubMedGoogle Scholar
  87. 87.
    Ferrarese C, Begni B, Canevari C, et al. Glutamate uptake is decreased in platelets from Alzheimer's disease patients. Ann Neurol. 2000;47:641–643PubMedGoogle Scholar
  88. 88.
    Zoia C, Cogliati T, Tagliabue E, et al. Glutamate transporters in platelets: EAAT1 decrease in aging and in Alzheimer's disease. Neurobiol Aging. 2004;25:149–157PubMedGoogle Scholar
  89. 89.
    do Nascimento CA, Nogueira CW, Borges VC, et al. Changes in [(3)H]-glutamate uptake into platelets from patients with bipolar I disorder. Psychiatry Res. 2006;141:343–347PubMedGoogle Scholar
  90. 90.
    Genever PG, Wilkinson DJP, Patton AJ, et al. Expression of a functional N-methyl-D-aspartate-type glutamate receptor by bone marrow megakaryocytes. Blood. 1999;23:2876–2883Google Scholar
  91. 91.
    Reilmann R, Rolf LH, Lange HW. Huntington's disease: N-methyl-D-aspartate receptor coagonist glycine is increased in platelets. Exp Neurol. 1997;144:416–419PubMedGoogle Scholar
  92. 92.
    Franconi F, Micele M, De Montis MG, et al. NMDA receptors play an anti-aggregating role in human platelets. Thromb Haemost. 1996;76:84–87PubMedGoogle Scholar
  93. 93.
    Franconi F, Miceli M, Alberti L, et al. Further insights into the anti-aggregating activity of NMDA in human platelets. Br J Pharmacol. 1998;124:35–40PubMedGoogle Scholar
  94. 94.
    Begni B, Tremolizzo L, D'Orlando C, et al. Substrate-induced modulation of glutamate uptake in human platelets. Br J Pharmacol. 2005;145:792–799PubMedGoogle Scholar
  95. 95.
    Borges VC, Santos FW, Rocha JB, et al. Heavy metals modulate glutamatergic system in human platelets. Neurochem Res. 2007;32:953–958PubMedGoogle Scholar
  96. 96.
    Tremolizzo L, DiFrancesco JC, Rodriguez-Menendez V, et al. Human platelets express the synaptic markers VGLUT1 and 2 and release glutamate following aggregation. Neurosci Lett. 2006;404:262–265PubMedGoogle Scholar
  97. 97.
    Sarchielli P, Di Filippo M, Candeliere A, et al. Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. J Neuroimmunol. 2007;188:146–158PubMedGoogle Scholar
  98. 98.
    Lombardi G, Dianzani C, Miglio G, et al. Characterization of ionotropic glutamate receptors in human lymphocytes. Br J Pharmacol. 2001;133:936–944PubMedGoogle Scholar
  99. 99.
    Ganor Y, Besser M, Ben-Zakay N, et al. Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. J Immunol. 2003;170:4362–4372PubMedGoogle Scholar
  100. 100.
    Chiocchetti A, Miglio G, Mesturini R, et al. Group I mGlu receptor stimulation inhibits activation-induced cell death of human T lymphocytes. Br J Pharmacol. 2006;148:760–768PubMedGoogle Scholar
  101. 101.
    Miglio G, Varsaldi F, Dianzani C, et al. Stimulation of group I metabotropic glutamate receptors evokes calcium signals and c-jun and c-fos gene expression in human T cells. Biochem Pharmacol. 2005;70:189–199PubMedGoogle Scholar
  102. 102.
    Miglio G, Varsaldi F, Lombardi G. Human T lymphocytes express N-methyl-D-aspartate receptors functionally active in controlling T cell activation. Biochem Biophys Res Commun. 2005;338:1875–1883PubMedGoogle Scholar
  103. 103.
    Connolly GP. Fibroblast models of neurological disorders: fluorescence measurement studies. Trends Pharmacol Sci. 1998;19:171–177PubMedGoogle Scholar
  104. 104.
    Balcar VJ, Shen J, Bao S, et al. Na(+)-dependent high affin-ity uptake of L-glutamate in primary cultures of human fibroblasts isolated from three different types of tissue. FEBS Lett. 1994;339:50–54PubMedGoogle Scholar
  105. 105.
    Zoia CP, Tagliabue E, Isella V, et al. Fibroblast glutamate transport in aging and in AD: correlations with disease severity. Neurobiol Aging. 2005;26:825–832PubMedGoogle Scholar
  106. 106.
    Castillo J, Davalos A, Naveiro J, et al. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke. 1996;27:1060–1065PubMedGoogle Scholar
  107. 107.
    Davalos A, Castillo J, Serena J, et al. Duration of glutamate release after acute ischemic stroke. Stroke. 1997;28:708–710PubMedGoogle Scholar
  108. 108.
    Serena J, Leira R, Castillo J, et al. Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters. Stroke. 2001;32:1154–1161PubMedGoogle Scholar
  109. 109.
    Davalos A, Shuaib A, Wahlgren NG. Neurotransmitters and pathophysiology of stroke: evidence for the release of glutamate and other transmitters/mediators in animals and humans. J Stroke Cerebrovasc Dis. 2000;9:2–8PubMedGoogle Scholar
  110. 110.
    Mallolas J, Hurtado O, Castellanos M, et al. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke. J Exp Med. 2006;203:711–717PubMedGoogle Scholar
  111. 111.
    Aliprandi A, Longoni M, Stanzani L, et al. Increased plasma glutamate in stroke patients might be linked to altered platelet release and uptake. J Cereb Blood Flow Metab. 2005;25:513–519PubMedGoogle Scholar
  112. 112.
    Cananzi AR, D'Andrea G, Perini F, et al. Platelet and plasma levels of glutamate and glutamine in migraine with and without aura. Cephalalgia. 1995;15:132–135PubMedGoogle Scholar
  113. 113.
    Sharp CD, Hines I, Houghton J, et al. Glutamate causes a loss in human cerebral endothelial barrier integrity through activation of NMDA receptor. Am J Physiol Heart Circ Physiol. 2003;285:2592–2598Google Scholar
  114. 114.
    Fujimoto T, Suzuki H, Tanque K, et al. Cerebrovascular injuries induced by activation of platelets in vivo. Stroke. 1985;16:245–250PubMedGoogle Scholar
  115. 115.
    Ballabh P, Braun A, Nedergaard M. The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1–13PubMedGoogle Scholar
  116. 116.
    Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391–397PubMedGoogle Scholar
  117. 117.
    Sherwin A, Robitaille Y, Quesney F, et al. Excitatory amino acids are elevated in human epileptic cerebral cortex. Neurology. 1988;38:920–923PubMedGoogle Scholar
  118. 118.
    Marrannes R, Willems R, De Prins E, et al. Evidence for a role of the N-methyl-D-aspartate (NMDA) receptor in cortical spreading depression in the rat. Brain Res. 1998;457:226–240Google Scholar
  119. 119.
    Ramadan NM, Halvorson H, Vande-Linde A, et al. Low brain magnesium in migraine. Headache. 1989;29:416–419PubMedGoogle Scholar
  120. 120.
    Schaumburg HH, Byck R, Gerstl R, et al. Monosodium 1-glutamate: its pharmacology and role in the Chinese restaurant syndrome. Science. 1969;163:826–828PubMedGoogle Scholar
  121. 121.
    Alam Z, Coombes N, Waring RH, et al. Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache. J Neurol Sci. 1998;156:102–106PubMedGoogle Scholar
  122. 122.
    Ferrari MD, Odink K, Bos KD, et al. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology. 1990;40:1582–1586PubMedGoogle Scholar
  123. 123.
    D'Andrea G, Cananzi AR, Joseph R, et al. Platelet glycine, glutamate and aspartate in primary headache. Cephalalgia. 1991;11:197–200PubMedGoogle Scholar
  124. 124.
    Martìnez F, Castillo J, Rodrìguez JR, et al. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia. 1993;13:89–93PubMedGoogle Scholar
  125. 125.
    Hanington E. The platelet and migraine. Headache. 1986;26:411–415PubMedGoogle Scholar
  126. 126.
    Vaccaro M, Riva C, Tremolizzo L, et al. Platelet glutamate uptake and release in migraine with and without aura. Cephalalgia. 2007;27:35–40PubMedGoogle Scholar
  127. 127.
    Rainesalo S, Keränen T, Peltola J, et al. Glutamate uptake in blood platelets from epileptic patients. Neurochem Int. 2003;43:389–392PubMedGoogle Scholar
  128. 128.
    D'Andrea G, Nordera GP, Allais G. Treatment of aura: solving the puzzle. Neurol Sci. 2006;27(2, Suppl):96–99Google Scholar
  129. 129.
    Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr. 1997;9(1, Suppl): 173–176PubMedGoogle Scholar
  130. 130.
    Small GW, Komo S, La Rue A, et al. Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann N Y Acad Sci. 1996;802:70–78PubMedGoogle Scholar
  131. 131.
    Masliah E, Alford M, DeTeresa R, et al. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol. 1996;40:759–766PubMedGoogle Scholar
  132. 132.
    Li S, Mallory M, Alford M, et al. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol. 1997;56:901–991PubMedGoogle Scholar
  133. 133.
    Masliah E, Raber J, Alford M, et al. Amyloid protein precursor stimulates excitatory amino acid transport. Implications for roles in neuroprotection and pathogenesis. J Biol Chem. 1998;273:12548–12554PubMedGoogle Scholar
  134. 134.
    Galimberti D, Fenoglio C, Lovati C, et al. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol Aging. 2006;27:1763–1768PubMedGoogle Scholar
  135. 135.
    Licastro F, Grimaldi LM, Bonafè M, et al. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging. 2003;24:921–926PubMedGoogle Scholar
  136. 136.
    Sala G, Galimberti G, Canevari C, et al. Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol Aging. 2003;24:909–914PubMedGoogle Scholar
  137. 137.
    Scott HL, Pow DV, Tannenberg AE, et al. Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease. J Neurosci. 2002;22:RC206PubMedGoogle Scholar
  138. 138.
    Iwatsuji K, Nakamura S, Kameyama M. Lymphocyte glutamate dehydrogenase activity in normal aging and neurological diseases. Gerontology. 1989;35:218–224PubMedGoogle Scholar
  139. 139.
    Peeters MA, Salabelle A, Attal N, et al. Excessive glu-tamine sensitivity in Alzheimer's disease and Down syndrome lymphocytes. J Neurol Sci. 1995;133:31–41PubMedGoogle Scholar
  140. 140.
    Walton HS, Dodd PR. Glutamate-glutamine cycling in Alzheimer's disease. Neurochem Int. 2007;50:1052–1066PubMedGoogle Scholar
  141. 141.
    Boldyrev AA, Johnson P. Homocysteine and its derivatives as possible modulators of neuronal and non-neuronal cell glutamate receptors in Alzheimer's disease. J Alzheimers Dis. 2007;11:219–228PubMedGoogle Scholar
  142. 142.
    Begni B, Brighina L, Sirtori E, et al. Oxidative stress impairs glutamate uptake in fibroblasts from patients with Alzheimer's disease. Free Radic Biol Med. 2004;37:892–901PubMedGoogle Scholar
  143. 143.
    Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging. 1998;19:33–36PubMedGoogle Scholar
  144. 144.
    Lovell MA, Ehmann WD, Mattson MP, et al. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging. 1997;18:457–461PubMedGoogle Scholar
  145. 145.
    Blanc EM, Keller JN, Fernandez S, et al. 4-Hydroxynonenal, a lipid peroxidation product, impairs glutamate transport in cortical astrocytes. Glia. 1998;22:149–160PubMedGoogle Scholar
  146. 146.
    Lauderback CM, Hackett JM, Huang FF, et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1–42. J. Neurochem. 2001;78:413–416PubMedGoogle Scholar
  147. 147.
    Jiménez-Jiménez FJ, Molina JA, Gómez P, et al. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease. J Neural Transm. 1998;105:269–277PubMedGoogle Scholar
  148. 148.
    Miulli DE, Norwell DY, Schwartz FN. Plasma concentrations of glutamate and its metabolites in patients with Alzheimer's disease. J Am Osteopath Assoc. 1993;93:670–676PubMedGoogle Scholar
  149. 149.
    Basun H, Forssell LG, Almkvist O, et al. Amino acid concentrations in cerebrospinal fluid and plasma in Alzheimer's disease and healthy control subjects. J Neural Transm Park Dis Dement Sect. 1990;2:295–304PubMedGoogle Scholar
  150. 150.
    Davydova T V, Voskresenskaya NI, Fomina VG, et al. Induction of autoantibodies to glutamate in patients with Alzheimer's disease. Bull Exp Biol Med. 2007;143:182–183PubMedGoogle Scholar
  151. 151.
    Ferrarese C, Aliprandi A, Tremolizzo L, et al. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology. 2001;57:671–675PubMedGoogle Scholar
  152. 152.
    Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 2003;53(3, Suppl):S26–S38PubMedGoogle Scholar
  153. 153.
    Shulman LM. Levodopa toxicity in Parkinson disease: reality or myth? Reality – practice patterns should change. Arch Neurol. 2000;57:406–407PubMedGoogle Scholar
  154. 154.
    Weiner WJ. Is levodopa toxic? Arch Neurol. 2000;57: 408–410PubMedGoogle Scholar
  155. 155.
    Greenamyre JT. Glutamatergic influences on the basal ganglia. Clin Neuropharmacol. 2001;24:65–70PubMedGoogle Scholar
  156. 156.
    Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol. 1998;44(1, Suppl):S175–S188PubMedGoogle Scholar
  157. 157.
    Ferrarese C, Zoia C, Pecora N, et al. Reduced platelet glutamate uptake in Parkinson's disease. J Neural Transm. 1999;106:685–692PubMedGoogle Scholar
  158. 158.
    Ferrarese C, Tremolizzo L, Rigoldi M, et al. Decreased platelet glutamate uptake and genetic risk factors in patients with Parkinson's disease. Neurol Sci. 2001;22:65–66PubMedGoogle Scholar
  159. 159.
    Zipp F, Demisch L, Derouiche A, et al. Glutamine syn-thetase activity in patients with Parkinson's disease. Acta Neurol Scand. 1998;97:300–302PubMedGoogle Scholar
  160. 160.
    Winkler-Stuck K, Wiedemann FR, Wallesch CW, et al. Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients. J Neurol Sci. 2004;220:41–48PubMedGoogle Scholar
  161. 161.
    Iwasaki Y, Ikeda K, Shiojima T, et al. Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson's disease. Neurosci Lett. 1992;145:175–177PubMedGoogle Scholar
  162. 162.
    Molina JA, Gómez P, Vargas C, et al. Neurotransmitter amino acid in cerebrospinal fluid of patients with dementia with Lewy bodies. J Neural Transm. 2005;112:557–563PubMedGoogle Scholar
  163. 163.
    Hartai Z, Klivenyi P, Janaky T, et al. Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. J Neurol Sci. 2005;239:31–35PubMedGoogle Scholar
  164. 164.
    Klivényi P, Toldi J, Vécsei L. Kynurenines in neurodegen-erative disorders: therapeutic consideration. Adv Exp Med Biol. 2004;541:169–183PubMedGoogle Scholar
  165. 165.
    Deng HX, Hentati A, Tainer JA, et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dis-mutase. Science. 1993;261:1047–1051PubMedGoogle Scholar
  166. 166.
    Wiedau-Pazos M, Goto JJ, Rabizadeh S, et al. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science. 1996;271:515–518PubMedGoogle Scholar
  167. 167.
    Yim HS, Kang JH, Chock PB, et al. A familial amyotrophic lateral sclerosis-associated A4 V Cu, Zn-superoxide dis-mutase mutant has a lower Km for hydrogen peroxide. Correlation between clinical severity and the Km value. J Biol Chem. 1997;272:8861–8863PubMedGoogle Scholar
  168. 168.
    Estevez AG, Crow JP, Sampson JB, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-defi-cient superoxide dismutase. Science. 1999;286:2498–2500PubMedGoogle Scholar
  169. 169.
    Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992;326:1464–1468PubMedGoogle Scholar
  170. 170.
    Shaw PJ, Chinnery RM, Ince PG. [3H]D-aspartate binding sites in the normal human spinal cord and changes in motor neuron disease: a quantitative autoradiographic study. Brain Res. 1994;655:195–201PubMedGoogle Scholar
  171. 171.
    Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 1998;20:589–602PubMedGoogle Scholar
  172. 172.
    Ince P, Stout N, Shaw P, et al. Parvalbumin and calbindin D-28 k in the human motor system and in motor neuron disease. Neuropathol Appl Neurobiol. 1993;19:291–299PubMedGoogle Scholar
  173. 173.
    Urushitani M, Shimohama S, Kihara T, et al. Mechanism of selective motor neuronal death after exposure of spinal cord to glutamate: involvement of glutamate-induced nitric oxide in motor neuron toxicity and nonmotor neuron protection. Ann Neurol. 1998;44:796–807PubMedGoogle Scholar
  174. 174.
    Takuma H, Kwak S, Yoshizawa T, et al. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol. 1999;46:806–815PubMedGoogle Scholar
  175. 175.
    Louvel E, Hugon J, Doble A. Therapeutic advances in amy-otrophic lateral sclerosis. Trends Pharmacol Sci. 1997;18:196–203PubMedGoogle Scholar
  176. 176.
    Shaw PJ, Kuncl RW. Current concepts in the pathogenesis of ALS. In: Kuncl RW (ed.) Motor Neuron Disease. W.B. Saunders, London, 2002Google Scholar
  177. 177.
    Williams TL, Day NC, Ince PG, et al. Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann Neurol. 1997;42:200–207PubMedGoogle Scholar
  178. 178.
    Trotti D, Rossi D, Gjesdal O, et al. Peroxynitrite inhibits glutamate transporter subtypes. J Biol Chem. 1996;271:5976–5979PubMedGoogle Scholar
  179. 179.
    Pedersen WA, Fu W, Keller JN, et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol. 1998;44:819–824PubMedGoogle Scholar
  180. 180.
    Trotti D, Rolfs A, Danbolt NC, et al. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci. 1999;2:427–433PubMedGoogle Scholar
  181. 181.
    Sala G, Beretta S, Ceresa C, et al. Impairment of glutamate transport and increased vulnerability to oxidative stress in neuroblastoma SH-SY5Y cells expressing a Cu, Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis. Neurochem Int. 2005;46:227–234PubMedGoogle Scholar
  182. 182.
    Ferrarese C, Sala G, Riva R, et al. Decreased platelet glutamate uptake in patients with amyotrophic lateral sclerosis. Neurology. 2001;56:270–272PubMedGoogle Scholar
  183. 183.
    Houi K, Kobayashi T, Kato S, et al. Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2002;106:299–301PubMedGoogle Scholar
  184. 184.
    Gluck MR, Thomas RG, Sivak MA. Unaltered cytochrome oxidase, glutamate dehydrogenase and glutaminase activities in platelets from patients with sporadic amyotrophic lateral sclerosis — a study of potential pathogenetic mechanisms in neurodegenerative diseases. J Neural Transm. 2000;107:1437–1447PubMedGoogle Scholar
  185. 185.
    Lanius RA, Paddon HB, Mezei M, et al. A role for ampli-fied protein kinase C activity in the pathogenesis of amyo-trophic lateral sclerosis. J Neurochem. 1995;65:927–930PubMedGoogle Scholar
  186. 186.
    Curti D, Malaspina A, Facchetti G, et al. Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes. Neurology. 1996;47:1060–1064PubMedGoogle Scholar
  187. 187.
    Poulopoulou C, Davaki P, Koliaraki V, et al. Reduced expression of metabotropic glutamate receptor 2mRNA in T cells of ALS patients. Ann Neurol. 2005;58:946–949PubMedGoogle Scholar
  188. 188.
    Jansen GA, Wanders RJ, Jobsis GJ, et al. Evidence against increased oxidative stress in fibroblasts from patients with non-superoxide-dismutase-1 mutant familial amyotrophic lateral sclerosis. J Neurol Sci. 1996;139(Suppl):91–94PubMedGoogle Scholar
  189. 189.
    Aguirre T, Van Den Bosch L, Goetschalckx K, et al. Increased sensitivity of fibroblasts from amyotrophic lateral sclerosis patients to oxidative stress. Ann Neurol. 1998;43:452–457PubMedGoogle Scholar
  190. 190.
    Cooper B, Chebib M, Shen J, et al. Structural selectivity and molecular nature of L-glutamate transport in cultured human fibroblasts. Arch Biochem Biophys. 1998;353:356–364PubMedGoogle Scholar
  191. 191.
    Sala G, Trombin F, Mattavelli L, et al. Lack of Evidence for Oxidative Stress in Sporadic Amyotrophic Lateral Sclerosis Fibroblasts. Neurodegener Dis. 2008 Mar 18 [Epub ahead of print]Google Scholar
  192. 192.
    Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol. 1990;28:18–25PubMedGoogle Scholar
  193. 193.
    Iwasaki Y, Ikeda K, Kinoshita M. Plasma amino acid levels in patients with amyotrophic lateral sclerosis. J Neurol Sci. 1992;107:219–222PubMedGoogle Scholar
  194. 194.
    Gredal O, Møller SE. Effect of branched-chain amino acids on glutamate metabolism in amyotrophic lateral sclerosis. J Neurol Sci. 1995;129:40–43PubMedGoogle Scholar
  195. 195.
    Plaitakis A, Caroscio JT. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol. 1987;22: 575–579PubMedGoogle Scholar
  196. 196.
    Perry TL, Krieger C, Hansen S, et al. Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid. Ann Neurol. 1990;28:12–17PubMedGoogle Scholar
  197. 197.
    Camu W, Billiard M, Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurol Scand. 1993;88:51–55PubMedGoogle Scholar
  198. 198.
    Ilzecka J, Stelmasiak Z, Solski J, et al. Plasma amino acids concentration in amyotrophic lateral sclerosis patients. Amino Acids. 2003;25:69–73PubMedGoogle Scholar
  199. 199.
    Spreux-Varoquaux O, Bensimon G, Lacomblez L, et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci. 2002;193:73–78PubMedGoogle Scholar
  200. 200.
    Andreadou E, Kapaki E, Kokotis P, et al. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis. In Vivo. 2008;22:137–141PubMedGoogle Scholar
  201. 201.
    Andreadou E, Kapaki E, Kokotis P, et al. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment. Clin Neurol Neurosurg. 2008;110:222–226PubMedGoogle Scholar
  202. 202.
    Brown MD. The enigmatic relationship between mitochon-drial dysfunction and Leber's hereditary optic neuropathy. J Neurol Sci. 1999;165:1–5PubMedGoogle Scholar
  203. 203.
    Luo X, Heidinger V, Picaud S, et al. Selective excitotoxic degeneration of adult pig retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci. 2001;42:1096–1106PubMedGoogle Scholar
  204. 204.
    Vorwerk CK, Naskar R, Schuettauf F, et al. Depression of retinal glutamate transporter function leads to elevated intravitreal glutamate levels and ganglion cell death. Invest Ophthalmol Vis Sci. 2000;41:3615–3621PubMedGoogle Scholar
  205. 205.
    Muller A, Maurin L, Bonne C. Free radicals and glutamate uptake in the retina. Gen Pharmacol. 1998;30:315–318PubMedGoogle Scholar
  206. 206.
    Beretta S, Mattavelli L, Sala G, et al. Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines. Brain. 2004;127:2183–2192PubMedGoogle Scholar
  207. 207.
    Beretta S, Wood JP, Derham B, et al. Partial mitochondrial complex I inhibition induces oxidative damage and perturbs glutamate transport in primary retinal cultures. Relevance to Leber Hereditary Optic Neuropathy (LHON). Neurobiol Dis. 2006;24:308–317PubMedGoogle Scholar
  208. 208.
    Sala G, Trombin F, Beretta S, et al. Antioxidants partially restore glutamate transport defect in leber hereditary optic neuropathy cybrids. J Neurosci Res. 2008 July 9 [Epub ahead of print]Google Scholar
  209. 209.
    Baracca A, Solaini G, Sgarbi G, et al. Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids. Arch Neurol. 2005;62:730–736PubMedGoogle Scholar
  210. 210.
    DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med. 2003;348:2656–2668PubMedGoogle Scholar
  211. 211.
    Schapira AH. Mitochondrial disease. Lancet. 2006;368: 70–82PubMedGoogle Scholar
  212. 212.
    Goto Y, Nonaka I, Horai S. A mutation in the tRNA (Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 1990;348: 651–653PubMedGoogle Scholar
  213. 213.
    Iizuka T, Sakai F. Pathogenesis of stroke-like episodes in MELAS: analysis of neurovascular cellular mechanisms. Curr Neurovasc Res. 2005;2:29–45PubMedGoogle Scholar
  214. 214.
    King MP, Koga Y, Davidson M, et al. Defects in mito-chondrial protein synthesis and respiratory chain activity segregate with the tRNA(Leu(UUR)) mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Mol Cell Biol. 1992; 12:480–490PubMedGoogle Scholar
  215. 215.
    Helm M, Florentz C, Chomyn A, et al. Search for differences in post-transcriptional modification patterns of mito-chondrial DNA-encoded wild-type and mutant human tRNALys and tRNALeu(UUR). Nucleic Acids Res. 1999;27:756–763PubMedGoogle Scholar
  216. 216.
    El Meziane A, Lehtinen SK, Hance N, et al. A tRNA suppressor mutation in human mitochondria. Nat Genet. 1998;18:350–353PubMedGoogle Scholar
  217. 217.
    Liu CY, Lee CF, Hong CH, et al. Mitochondrial DNA mutation and depletion increase the susceptibility of human cells to apoptosis. Ann N Y Acad Sci. 2004;1011:133–145PubMedGoogle Scholar
  218. 218.
    Pulkes T, Eunson L, Patterson V, et al. The mitochondrial DNA G13513A transition in ND5 is associated with a LHON/MELAS overlap syndrome and may be a frequent cause of MELAS. Ann Neurol. 1999;46:916–919PubMedGoogle Scholar
  219. 219.
    Blakely EL, de Silva R, King A, et al. LHON/MELAS overlap syndrome associated with a mitochondrial MTND1 gene mutation. Eur J Hum Genet. 2005;13:623–627PubMedGoogle Scholar
  220. 220.
    Wong A, Cavelier L, Collins-Schramm HE, et al. Differentiation-specific effects of LHON mutations introduced into neuronal NT2 cells. Hum Mol Genet. 2002;11:431–438PubMedGoogle Scholar
  221. 221.
    Yoneda M, Tanaka M, Nishikimi M, et al. Pleiotropic molecular defects in energy-transducing complexes in mitochondrial encephalomyopathy (MELAS). J Neurol Sci. 1989;92:143–158PubMedGoogle Scholar
  222. 222.
    Sandhu JK, Sodja C, McRae K, et al. Effects of nitric oxide donors on cybrids harbouring the mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) A3243G mitochondrial DNA mutation. Biochem J. 2005;391:191–202PubMedGoogle Scholar
  223. 223.
    Wong A, Cortopassi G. mtDNA mutations confer cellular sensitivity to oxidant stress that is partially rescued by calcium depletion and cyclosporin A. Biochem Biophys Res Commun. 1997;239:139–145PubMedGoogle Scholar
  224. 224.
    Pang CY, Lee HC, Wei YH. Enhanced oxidative damage in human cells harboring A3243G mutation of mitochondrial DNA: implication of oxidative stress in the pathogenesis of mitochondrial diabetes. Diabetes Res Clin Pract. 2001;54(2, Suppl):S45–S56PubMedGoogle Scholar
  225. 225.
    Rusanen H, Majamaa K, Hassinen IE. Increased activities of antioxidant enzymes and decreased ATP concentration in cultured myoblasts with the 3243A→G mutation in mito-chondrial DNA. Biochim Biophys Acta. 2000;1500:10–16PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Lucio Tremolizzo
    • 1
  • Gessica Sala
    • 2
  • Carlo Ferrarese
    • 3
  1. 1.Neurologist and Post-doctoral Research AssociateUniversity of Milano-Bicocca; Ospedale San GerardoMonzaItaly
  2. 2.Post-doctoral Research Associate, Department of Neuroscience and Biomedical TechnologiesUniversity of Milano-BicoccaItaly
  3. 3.Director of the Department of Neurology and of the Neurology Residency SchoolUniversity of Milano-Bicocca, Ospedale San GerardoMonzaItaly

Personalised recommendations